secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0001999371-23-000907
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals enters $11M term loan with JGB entities; reviews Phase 2 migraine data
--------------------------------------------------------------------------------

- $11.0M 36-month term loan from JGB Capital, JGB Partners, JGB (Cayman) Cornish Rock; interest at Prime+3.5% floor 12%.
- Loan secured by R&D center in Frederick, MD, and Advanced Development Center in North Dartmouth, MA, and deposit accounts.
- Prepayment premium: $700K if paid by Dec 2024, $1M if by Dec 2025, $1.3M thereafter.
- Company analyzing Phase 2 proof-of-concept results for TNX-1900 (intranasal potentiated oxytocin) for chronic migraine; expects completion by late Dec 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937123000907/0001999371-23-000907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937123000907/tnxp_8k-120823.htm
  HTML page:      https://secwatch.observer/filing/0001999371-23-000907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer